Welcome
Please select one of the following options
The content on this website is intended for healthcare professionals only.
The website contains both promotional and non-promotional content.
INDICATION STATEMENT:
Koselugo® as a monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PNs) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.1
ADVERSE EVENT STATEMENT:
▼Adverse events can be reported to AstraZeneca by visiting
https://contactazmedical.astrazeneca.com.
PRESCRIBING INFORMATION:
Refer to MY prescribing information before prescribing.
Abbreviations:
MY, Malaysia; NF1, neurofibromatosis type 1; PN, plexiform neurofibroma.
References:
- Koselugo® Malaysia Prescribing Information. Doc ID-004754615. Version 4.0. Last revised on October 2024.
